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crosses of a worldwide collection of
barley cultivars and landraces with a
btr1 or btr2 tester (Pourkheirandish
et al., 2015). In both cases, the 1bp and
11bp deletions of the btr1 and btr2 alleles,
respectively, were demonstrated to be
monophyletic. In their survey for shared
haplotypes, the immediate wild ancestors
of btr1 were confined to varieties of Jor-
dan, Israel, and Turkmenistan, Uzbeki-
stan, and Afghanistan, suggesting the
Southern Levant and Central Asia as
domestication centers. The analysis re-
veals a second independent domestica-
tion center for btr2-type cultivars in the
Northern Levant comprising North Syria
and the southeast of Turkey. From these
two confined areas, barley cultivation
spread and rendered the grain that is the
world’s fourth most important crop today,
globally grown as mainly animal feed and
brewing malt (Figure 1A).The cloning and physiological charac-
terization of the barley Btr genes provide
novel insights into the evolution and
domestication of different clade- and
species-specific mechanisms of seed
dispersal systems in grasses. Different
genes and molecular mechanisms for
seed shattering in rice and barley, as
well as the absence of rice seed shatter-
ing QTLs in regions syntenic to the barley
Btr genes, are apparent. This suggests a
novel—or at least modified—pathway in
the Pooideae. However, additional func-
tional analysis of these loci in rice and
other cereals is required to test this hy-
pothesis. This will help to understand
the fascinating evolution and parallel
domestication of the seed dispersal sys-
tem and will be instructive about the mo-
lecular basis that laid the foundation for
the cultural development of modern
societies.CellREFERENCES
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Although the mitochondrial electron transport chain (ETC) is best known for its role in ATP synthe-
sis, two studies, Sullivan et al. and Birsoy et al., conclude that its only essential function in prolifer-
ating cells is making aspartate (D).Within the inner mitochondrial membrane,
73 individual subunits translated from
two distinct genomes are assembled
into the four multimeric protein com-
plexes that comprise the electron trans-
port chain (ETC). This machine of
unrivaled complexity and elegance plays
a critical role in enabling the mitochondria
to synthesize 34 molecules of ATP
from the oxidization of one molecule of
glucose. Therefore, it may be surprising
that two papers published in this issue of
Cell (Sullivan et al., 2015; Birsoy et al.,
2015) provide compelling evidence that
in proliferating cells the only essential
function of these massive complexes is
the biosynthesis of a single, seem-ingly insignificant, amino acid—aspartate,
known tomost scientists only as Asp or D.
The story starts with an observation
made some 25 years ago by King and
Attardi (1989), who demonstrated that
cells lacking mtDNA failed to proliferate
as a result of ETC dysfunction, but that
this could be rescued by adding supra-
physiological concentrations of pyruvate
to the media. While many of us have
encountered this fact when culturing
mammalian cells, the etiology of this phe-
nomenon is not at all obvious. Why would
pyruvate rescue the growth of cells lack-
ing functional mtDNA, which are highly
glycolytic and generate large amounts of
pyruvate inherently (which is typicallyconverted to lactate and excreted)? Sulli-
van et al. and Birsoy et al. clearly show
that ETC dysfunction impairs the redox
balance of the cell and that the operative
role of pyruvate is to restore redox ho-
meostasis by serving as an electron
acceptor.
The ETC enables the passage of an
electron from NADH (leaving NAD+) to
O2 (resulting in H2O). As a result, loss of
ETC function not only blocks mitochon-
drial ATP synthesis, it also causes a
decrease in the NAD+ pool and NAD+/
NADH ratio. Based on this rationale, Sulli-
van et al. hypothesize that the pro-prolif-
erative capability of pyruvate may be to
accept electrons and regenerate NAD+162, July 30, 2015 ª2015 Elsevier Inc. 471
Figure 1. Aspartate Biosynthesis in Normal
andElectronTransportChain-DeficientCells
(A) A simplified overview of glycolysis, the tricar-
boxylic acid (TCA) cycle and the malate-aspartate
shuttle (shaded in green) in normal cells, and their
contribution of essential precursors for the
biosynthesis of nucleotides, fatty acids, and amino
acids. The electron transport chain (ETC) and other
processes that drive NAD+/NADH balance are
indicated. Right: The green arrows andmetabolites
represent the primary aspartate biosynthetic sys-
tems operating in normal, ETC-deficient. and
pyruvate supplemented ETC-deficient cells as
described in Birsoy et al. (2015).
(B) Normal respiring cells utilize an oxidative
aspartate biosynthetic pathway in which malate
dehydrogenase (MDH2)-derived oxaloacetate is
used as the primary substrate for glutamate-
oxaloacetate transaminase (GOT2)-dependent
aspartate biosynthesis in the mitochondria. This
pathway requires a functional electron transport
chain to oxidize mitochondrial NADH to NAD+,
which is an essential cofactor of MDH2.
(C) ETC deficiency causes a decreased NAD+/
NADH ratio, which forces cells to utilize a reductive
aspartate biosynthetic pathway. ATP-citrate lyase
(ACL) uses citrate derived from reductive carbox-
ylation of glutamine to generate cytosolic oxalo-
acetate, which is converted to aspartate by GOT1.
Upon full inhibition of the ETC, this pathway fails to
generate sufficient aspartate to promote normal
cell proliferation.
(D) Exogenous pyruvate treatment enables aspar-
tate biosynthesis and cell proliferation in ETC-
deficient cells. Glycolytic production of pyruvate
and then conversion to lactate by lactate dehy-
drogenase (LDH) has no net effect on the NAD+/
NADH ratio. Exogenous pyruvate, on the other
hand, bypasses glycolysis and reduction by LDH
leads to a net gain in NAD+, enabling MDH1 to
generate oxaloacetate for conversion to aspartate
by GOT1. The source of cytosolic malate remains
unclear but could either be derived from pyruvate
via the malic enzyme, or from TCA cycle activity
enabled by the presumably increased NAD+/NADH
ratio in the mitochondria.
As illustrated in both (C) and (D), GOT1 is essen-
tial for aspartate biosynthesis in cells with an
impaired ETC.
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tion. To test this hypothesis, the authors
treat ETC-deficient cells with a-ketobuty-
rate (AKB), which can also be reduced by
LDH and regenerate NAD+, but is not
further metabolized to generate ATP or
for other purposes. Indeed, AKB, like py-
ruvate, is sufficient to restore proliferation
in these cells, and both treatments restore
the normal NAD+/NADH ratio in the face of
ongoing ETC impairment.
To further understand the metabolic
consequences of electron acceptor defi-
ciency, each group independently interro-
gate the steady-state abundance of
cellular metabolites. Among other pertur-
bations, the authors observe a striking
decrease in aspartate that is fully rescued
by addition of exogenous AKB (Sullivan
et al., 2015) or pyruvate (Birsoy et al.,
2015). Aspartate biosynthesis normally
occurs in the mitochondria and requires
mitochondrial malate dehydrogenase
(MDH2) and its obligate NAD+ co-sub-
strate (Figure 1A). As a result, uncompen-
sated ETC inhibition and NAD+ depletion
causes failure of the canonical pathway
of aspartate synthesis. In perhaps the
most surprising result of the two papers,
however, addition of only exogenous
aspartate is sufficient to restore pro-
liferative capacity to ETC-deficient cells
without affecting the redox state. Of
all the potential problems caused by
loss of ETC function, aspartate auxot-
rophy is the one that is rate limiting for
proliferation.
In parallel, Birsoy et al. take the forward
genetic approach of asking cells which
metabolic pathways are important for
proliferation in the presence of ETC inhibi-
tion. The cells speak loud and clear, and
the message again is about aspartate.
The top hit that emerges from the screen
is GOT1, a cytosolic aspartate amino-
transferase involved in the malate-aspar-
tate shuttle (Figure 1). The authors go on
to confirm that the aspartate synthesis
and proliferation of cells with GOT1 dele-
tion are much more sensitive to all forms
of ETC impairment than their wild-type
counterparts. Flux labeling experiments
reveals that ETC competent cells synthe-
size aspartate through a mitochondrial
oxidative pathway from TCA cycle-
derived oxaloacetate (Figure 1B). ETC-
deficient cells, without sufficient NAD+,
switch to a reductive biosynthetic path-
way in which citrate, derived from
reductive carboxylation of glutamine, is
converted to oxaloacetate by ATP-citrate
lyase, which can be used by GOT1
to generate aspartate in the cytosol
(Figure 1C). This pathway, however, is
not capable of synthesizing sufficient
aspartate to support normal cell prolifera-
tion without a continuous supply of
oxidized NAD+. This brings the story
back to pyruvate and AKB as exogenous
electron acceptors, which regenerate the
pool of cytosolic NAD+ to enable a third
aspartate biosynthetic pathway requiring
both GOT1 and MDH1, the NAD+-
requiring cytosolic malate dehydroge-
nase (Figure 1D).These two studies provide profound
and surprising insights into the metabolic
consequences of ETC dysfunction and
raise questions about how this plays out
in a living mammal. These experiments
focus on proliferating cells in culture.
Would ETC dysfunction in highly prolifera-
tive cells in vivo cause a similar decrease
in the NAD+/NADH ratio and cause a
similar dependency on exogenous aspar-
tate or pyruvate, which are maintained
at relatively low concentrations in the
blood (Kelsay et al., 1972; Wuu et al.,
1988)? Second, does ETC dysfunction
have similar metabolic consequences in
post-mitotic differentiated cells? Regard-
less of proliferative activity, depletion
of cellular electron acceptors will un-
doubtedly impair aspartate biosynthesis
and redox balance. In fact, Birsoy et al.
show that mitochondrial dysfunction
leads to local aspartate depletion in
mice with heart-specific deletion of
mitochondrial transcription factor A
(Tfam). These studies suggest that redox
imbalance and maybe even aspartate
depletion might be components of the
pathophysiology of human diseases of
impaired ETC function. If so, an enhanced
exogenous supply of pyruvate, AKB, or
aspartate may have therapeutic benefit,
for which there is already some evidence
(Fujii et al., 2014).
Some tumors are also characterized by
homozygous loss-of-function mutations
affecting the TCA cycle enzymes, succi-
nate dehydrogenase (SDH) and fumarate
hydratase (FH), which result in similarly
impaired mitochondrial ETC activity (Rai-
mundo et al., 2011). The data from the
two studies raise the possibility that
such tumor cells may be addicted to
exogenous pyruvate and/or aspartate for
proliferation. This is supported by the
recent finding that SDH-deficient cells
consume extracellular pyruvate, which
promotes aspartate biosynthesis (Eyal
Gottlieb, personal communication). If so,
it might be possible to exploit this liability
therapeutically in the treatment of SDH- or
FH-deficient tumors.
These studies also raise important but
difficult questions regarding the intracel-
lular compartmentalization of metabolite
pools, particularly of NAD+/NADH (Niki-
forov et al., 2015). Despite having drasticCelleffects of cell proliferation, ETC inhibition
causes only a very mild perturbation
(20%) in the NAD+/NADH ratio when
measured in cell lysates. The effect sizes
don’t seem to match and one possible
explanation is the compartmentalization
of distinct pools of NAD and NADH
that serve different metabolic functions.
Upon ETC dysfunction, there is likely a
massive depletion of NAD+ in the mito-
chondrial matrix, which is not detected
due to the overwhelmingly larger pool in
the cytosol, which is either normal or
mildly affected. There could also be spe-
cific cytosolic NAD+/NADH pools that
are particularly sensitive to ETC dysfunc-
tion. Such hypotheses await the advent
of new tools that can measure redox bal-
ance or metabolic flux with subcellular
spatial resolution.
These studies provide a new perspec-
tive on the function of the ETC. At least in
proliferating cells, the critical function of
this system is not the generation of ATP,
but rather to simply provide a route to O2
as a terminal electron acceptor. They
also add to the growing drumbeat pro-
claiming thecentral importanceof prolifer-
ating cells adjusting their metabolism to
support macromolecular biosynthesis
even at the expense of ATP synthesis.
And, who would have believed that the
one essential biosynthetic requirement
for the ETC is aspartate?REFERENCES
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